All In MedTech

Device Trial Radar · NCT03101501

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

Last checked: Nov 19, 2026Latest source record: Aug 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

Feb 14, 2017

Primary completion

Feb 1, 2018

Study completion Feb 1, 2018

Sponsor

Lead sponsor
Key-Whitman Eye CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 41 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical objective of this study is to evaluate the Raindrop® Near Vision Inlay for the improvement of near vision in presbyopic or pseudophakic patients treated with low dose Mitomycin C immediately following femtosecond flap creation.

Conditions

  • Presbyopia

Interventions

  • Mitomycin cDrug

    Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.

  • Raindrop Near Vision InlayDevice

    Implanted to improve near vision in Presbyopic or Pseudophakic subjects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uncorrected Visual AcuityTime frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Chu Vision Institue

    Bloomington, Minnesota

  • Key-Whitman Eye Center

    Dallas, Texas

  • Parkhurst NuVision

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.